

January 7, 2015



Boston Therapeutics to Present at 8th Annual OneMedForum Conference in San Francisco

CEO David Platt to Present on Tuesday, January 13 at 9:10 AM PT

MANCHESTER, NH -- (Marketwired) -- 01/07/15 -- Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, will be a presenting company at the 8th Annual OneMedForum Conference to be held at the San Francisco Marriott Marquis in San Francisco, CA.

David Platt, Ph.D., CEO of Boston Therapeutics, will give a presentation on Tuesday, January 13 at 9:10 AM PT on the Company's development of therapeutic molecules that address diabetes and inflammatory diseases, including BTI-320, a non-systemic chewable therapeutic compound designed to reduce post-meal glucose elevation, and sugardown®, a non-systemic complex carbohydrate-based dietary food supplement designed to support healthy blood glucose.

OneMedForum's objective is to assemble the most promising companies and technologies in health and medicine to connect with investors and executives. Since 2008, more than 400 companies have presented at OneMedForum, and almost 300 leading investors have served on panels.

About Boston Therapeutics, Inc.

Boston Therapeutics, headquartered in Manchester, NH, (OTCQB: BTHE) is an innovator in designing compounds using complex carbohydrate chemistry. The company's product pipeline is focused on developing and commercializing therapeutic molecules that address diabetes and inflammatory diseases, including: BTI-320, a non-systemic chewable therapeutic compound designed to reduce post-meal glucose elevation, and IPOXYN, an injectable anti-necrosis drug designed initially to treat lower limb ischemia associated with diabetes. The company also developed and markets sugardown®, a non-systemic complex carbohydrate-based dietary food supplement designed to support healthy blood glucose. More information is available at www.bostonti.com.

Cautionary Note Regarding Forward Looking Statements

This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ

materially from those discussed in the forward-looking statements include, among others, that our plans, expectations and goals regarding our clinical development of BTI-320 are subject to factors beyond our control. We can provide no assurance we or our commercial partner will be able to generate market demand for sugardown®, and thus we may not be able to generate revenue from sugardown® sales.

Moreover, we have incurred operating losses since our inception, and our ability to successfully develop, market, manufacture, distribute and sell drugs or over-the-counter products may be affected by our ability to manage costs and finance our continuing operations. For a discussion of additional risk and other factors affecting our business, see our Annual Report on Form 10-K for the year ended December 31, 2013, and our subsequent filings with the SEC.

You should not place undue reliance on forward-looking statements, and actual results may differ materially from the results anticipated in our forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

© Boston Therapeutics, Inc. All rights reserved.

Contact:

Boston Therapeutics, Inc.
Anthony Squeglia
Chief Financial Officer
Phone: 603-935-9799
Email: anthony.squeglia@bostonti.com
www.bostonti.com

Source: Boston Therapeutics